Entera Bio Ltd

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

OPKO Health

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss.

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.

Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?

Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Bitfarms Ltd

Cronos Group

Since 2021, meme stocks have been massive wealth creators for high-risk investors. During this period, dozens of meme stocks have delivered 5x to 10x returns within a few quarters.

3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years

Archer Aviation

The S&P 500 index is trading near record highs, and the overall outlook for the market is likely to remain bullish. While GDP growth has decelerated, the markets seem to be discounting multiple rate cuts in the next 12 to 18 months.

3 Meme Stocks That Can Surge by 200% Before 2025

Adicet Bio, Inc.

Actinium Pharmaceuticals

One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

Aurora Cannabis

Riot Blockchain

When meme stocks start skyrocketing, it's difficult to find a good entry point. Already, examples of a big rally in meme stocks happened in the recent past.

3 Meme Stocks to Buy on the Dip: June 2024

Blink Charging

Curaleaf Holdings, Inc.

Ring Energy

Standard Lithium Ltd

A few penny stocks have already surged recently on the back of an impending meme frenzy. Other penny stocks to buy have remained relatively subdued.

7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months

Joby Aviation

Solid Power

There are penny stocks to buy that represent purely speculative bets. In a meme frenzy, these stocks can deliver multibagger returns in the blink of an eye.

Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich

Blade Air Mobility

Investors looking for stocks with millionaire-maker potential must go overweight on growth and penny stocks. When it comes to penny ideas, the thing that comes to mind is speculation or a meme frenzy.

3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024

Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024

Atossa Genetics

In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed.

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.

Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?

Acasti Pharma

Karyopharm Therapeutics

Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Entera Bio (ENTX) This Year?

JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management.

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts.

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024.

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.

Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade

News for Entera Bio Ltd Stock (ENTX)